ERBB2 and neoplasm: The 2023 ASCO/CAP (American Society of Clinical Oncology/College of American Pathologists) guideline recommends evaluating a minimum of 20 non-overlapping nuclei of tumor cells in two separate areas of invasive cancer when reporting the HER2 ISH test [5].